Congruence Therapeutics’ Post

Congruence Therapeutics is thrilled to sponsor the inaugural #GBA1 meeting, taking place this week at the The Neuro (Montreal Neurological Institute-Hospital), a research and medical center affiliated with McGill University and dedicated to neuroscience training and clinical care #Neuro. The meeting will serve as a unique platform to advance the understanding and treatment of GBA1-associated neurodegenerative diseases. Congruence is also pleased to announce the acceptance of its poster for presentation at the conference. The poster highlights continued advancement of Congruence’s discovery-stage program directed to GBA-driven Parkinson’s Disease. We look forward to sharing our progress with meeting attendees. For more information click here: https://bit.ly/4cs1Xhn #GBA1 #Parkinsons #neuro

Congruence Therapeutics is presenting at the Chemical Computing Group #UGM and Conference 2024, taking place June 25-28 in our hometown of Montreal. The event consists of workshops, scientific presentations, and a poster session. We will showcase our computational drug discovery engine and how we are leveraging it to build an exciting pipeline of small molecule correctors for diseases of protein misfolding. Come engage with us! Learn more here: https://bit.ly/3zkH21e #UGM #CCG #AI #ML

Our Chief Business Officer, Frank Taffy, will be at #BIO2024. We invite you to connect with us! #biotech #innovation #drugdiscovery #AI #ML

Invest Canada '24 kicks off in Montreal at the end of this month. Join our CEO, Dr. Clarissa Desjardins, at IC24 for the "Building World-Class Companies” panel session, where investors and CEOs discuss crucial ingredients and funding sources needed for high-growth businesses to thrive. Learn more here: https://lnkd.in/gvacksx #biotech #innovation #drugdiscovery #AI #ML

Thank you BIOTECanada for featuring our CEO, Dr. Clarissa Desjardins, in the latest issue of Insights Magazine! Check out page 34 of the article to read more about Dr. Desjardins and her path toward entrepreneurship that helped shape the future of our company. https://lnkd.in/gSfUnX6J #biotech #innovation #drugdiscovery #AI #BIOTECanada #ML

We continue to attract top talent to Congruence Therapeutics - join us in welcoming Michael Harvey as our Chief Development Officer!  Michael is a senior biotechnology executive with more than twenty years of experience in drug development, with expertise in a wide range of therapeutic areas including musculoskeletal rare diseases, obesity, oncology, and infectious diseases.     Learn more about his expertise and stellar background here: https://lnkd.in/gbfBV8Qm   #biotech #leadership #AI #ML

Congruence Therapeutics is pleased to have expanded our management team with experienced leaders like Frank Taffy. We look forward to Frank’s contributions as we build a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Learn more about our science and our approach here: https://lnkd.in/gaKEwTcA   #AI #ML #leadership